Search
Respiratory syncytial virus (RSV) is a significant cause of respiratory infections in young children. Since 2021, RSV has been a notifiable disease in Australia. However, current surveillance systems focus on hospitalised RSV, with limited surveillance at a community level through primary care clinics. This approach only captures RSV requiring hospitalisation. Less severe illnesses, while not captured, may have significant social and economic impacts including the associated cost of care and absenteeism. The aim of this study is to establish an understanding of the broader burden of RSV in young children in a community setting.
This study described the presenting features, initial assessment, hospital care, and complications at discharge among Australian adolescents and young adults with Invasive meningococcal disease.
Vancomycin is first-line treatment for methicillin-resistant Staphylococcus aureus infections. However, despite guideline recommendations, there is no evidence that targeting vancomycin trough concentrations of ≥15 mg/L in children confers clinical benefit and is associated with vancomycin-associated nephrotoxicity.
Despite vaccination, influenza and otitis media (OM) remain leading causes of illness. We previously found that the human respiratory commensal Haemophilus haemolyticus prevents bacterial infection in vitro and that the related murine commensal Muribacter muris delays OM development in mice. The observation that M muris pretreatment reduced lung influenza titer and inflammation suggests that these bacteria could be exploited for protection against influenza/OM.
Research reveals that friendly bacteria may help reduce flu symptoms, offering new insights into potential treatments and enhancing our understanding of immune health.
Understanding patterns of bacterial carriage and otitis media (OM) microbiology is crucial for assessing vaccine impact and informing policy. The microbiology of OM can vary with geography, time, and interventions like pneumococcal conjugate vaccines (PCVs). We evaluated the microbiology of nasopharyngeal and middle ear effusions in children living in Western Australia, 11 years following the introduction of PCV13.
Chris Glenn Lea-Ann Peter Ruth Brennan-Jones Pearson Kirkham Richmond Thornton PhD BA (Education) PhD Candidate PhD MBBS MRCP(UK) FRACP PhD Head, Ear
Deborah Lea-Ann Peter Ruth Strickland Kirkham Richmond Thornton PhD PhD MBBS MRCP(UK) FRACP PhD Head, Pregnancy and Early Life Immunology Co-Head,
A telehealth-facilitated randomised-controlled trial utilising a health promotion intervention to resolve otitis media with effusion for children won specialist Ear, Nose and Throat (ENT) waiting lists
Lea-Ann Peter Ruth Kirkham Richmond Thornton PhD MBBS MRCP(UK) FRACP PhD Co-Head, Bacterial Respiratory Infectious Disease Group; Microbiology Lead,